Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
caricotamide
- Development stage
- Phase 2
- Lead developer
- BTG International
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Caricotamide is a small molecule used as a **co-substrate** in the investigational chemotherapy combination **Prolarix**, where it is administered with tretazicar (also known as CB1954). The drug combination targets tumors by exploiting the enzyme **NQO2 (quinone oxidoreductase 2)** in tumor cells. Tretazicar serves as a prodrug that is bioactivated by NQO2 in the presence of caricotamide, leading to the formation of a potent **bifunctional DNA cross-linking agent** capable of inducing cytotoxic effects in cancer cells through DNA cross-linking. Prolarix was primarily developed for **liver cancer including hepatocellular carcinoma**, but development was discontinued in phase 2 trials.
- Brand names
- Prolarix
- Other names
- EP-0152REP0152REP 0152R
02
Targets
NQO2 (Ribosyldihydronicotinamide dehydrogenase [quinone])
Beyond the preview
Go deeper on caricotamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on caricotamide.